Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations
- PMID: 21724294
- DOI: 10.1016/j.jaad.2010.08.041
Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations
Abstract
Background: The condition that came to be known as nephrogenic systemic fibrosis (NSF) was first reported in 2000 and, in 2001, was termed "nephrogenic fibrosing dermopathy." Since then, NSF has been the subject of a wide-ranging multidisciplinary medical investigation that has proven an indisputable link to renal disease and a compelling association with the increasing use of gadolinium-containing magnetic resonance imaging contrast agents in the renally impaired.
Objective: Although precise causation and risk factors continue to be elucidated, the need for reproducible prospective epidemiologic data demands clear and objective criteria for the diagnosis of NSF.
Methods: Experts in NSF diagnosis used their experience and the resources of the Yale International NSF Registry to develop a clinicopathological diagnostic system for NSF.
Results: A consensus scoring system incorporating a clinical and histopathological atlas was devised to guide and standardize the evaluation and diagnosis of NSF.
Limitations: There is no laboratory test that can be used as a gold standard to diagnose NSF. To overcome this, we relied on classic clinicopathological presentations, published sources, and consensus clinical expertise to ensure the integrity of the study population.
Conclusion: The clinicopathological definition of NSF provides guidance to physicians for the evaluation and diagnosis of NSF. Clinical, laboratory, and histopathological features comprise a schema that excludes conditions mimicking NSF while facilitating its reproducible and accurate diagnosis, even among physicians with little prior clinical experience with this entity. This definition can serve as a working diagnostic standard for future research and as the basis for adjudicating borderline cases.
Copyright © 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
Similar articles
-
Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis.Ann Pharmacother. 2007 Sep;41(9):1481-5. doi: 10.1345/aph.1K295. Epub 2007 Aug 7. Ann Pharmacother. 2007. PMID: 17684032 Review.
-
Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: a primer for radiologists.J Comput Assist Tomogr. 2008 Jan-Feb;32(1):1-3. doi: 10.1097/RCT.0b013e31805d08ee. J Comput Assist Tomogr. 2008. PMID: 18303280 Review.
-
Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience.J Am Acad Dermatol. 2010 Sep;63(3):389-99. doi: 10.1016/j.jaad.2009.10.038. Epub 2010 Jul 8. J Am Acad Dermatol. 2010. PMID: 20619488
-
Nephrogenic systemic fibrosis: what internists need to know.Mo Med. 2009 Sep-Oct;106(5):373-6. Mo Med. 2009. PMID: 19902721 Review.
-
Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients.J Magn Reson Imaging. 2009 Dec;30(6):1335-40. doi: 10.1002/jmri.21976. J Magn Reson Imaging. 2009. PMID: 19937927
Cited by
-
Nephrogenic Systemic Fibrosis in Patients with Chronic Kidney Disease after the Use of Gadolinium-Based Contrast Agents: A Review for the Cardiovascular Imager.Diagnostics (Basel). 2022 Jul 28;12(8):1816. doi: 10.3390/diagnostics12081816. Diagnostics (Basel). 2022. PMID: 36010167 Free PMC article. Review.
-
Gadolinium Deposition Disease: A Case Report and the Prevalence of Enhanced MRI Procedures Within the Veterans Health Administration.Fed Pract. 2022 May;39(5):218-225. doi: 10.12788/fp.0258. Epub 2022 May 14. Fed Pract. 2022. PMID: 35935925 Free PMC article.
-
Risk of nephrogenic systemic fibrosis in patients with impaired renal function undergoing fixed-dose gadoxetic acid-enhanced magnetic resonance imaging.Abdom Radiol (NY). 2021 Aug;46(8):3995-4001. doi: 10.1007/s00261-021-03045-4. Epub 2021 Mar 20. Abdom Radiol (NY). 2021. PMID: 33742216
-
Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation.Kidney Med. 2020 Nov 10;3(1):142-150. doi: 10.1016/j.xkme.2020.10.001. eCollection 2021 Jan-Feb. Kidney Med. 2020. PMID: 33604544 Free PMC article. Review.
-
Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review.Ann Intern Med. 2020 Jul 21;173(2):110-119. doi: 10.7326/M20-0299. Epub 2020 Jun 23. Ann Intern Med. 2020. PMID: 32568573 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical